MetaCap

MoonLake Immunotherapeutics Class A (MLTX)

NASDAQ: MLTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

11.07+0.04 (+0.36%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MLTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$942.13M
EPS (TTM)
-$3.66
52-week range
9.46 – 23.29
Day range
10.73 – 11.30
Volume / Avg
1.72M / 1.64M
Beta
—

52-week range

$9.46$23.29

MLTX stock today

MoonLake Immunotherapeutics (MLTX) closed at $11.07 on Nov 20, up 0.36% (+$0.04), versus the S&P 500's 3.70% decline. Shares are 52.5% below their 52-week high of $23.29, set on Jun 22, 2026 and 17.0% above the 52-week low of $9.46, near the bottom of the past year's range. MLTX is down 16.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 12.6%.

MoonLake Immunotherapeutics has posted a net loss over the last twelve months (EPS of -$3.66), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About MoonLake Immunotherapeutics

Company profile

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Jorge Santos da Silva Ph.D.
Headquarters
Zug
Employees
130
IPO year
2020

Financial highlights

Full financials

MoonLake Immunotherapeutics reported a net loss of $227.3 million, compared with a loss of $118.9 million a year earlier. Diluted earnings per share came in at -$3.53.

MoonLake Immunotherapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-227.32M$-118.94M$-36.01M$-49.97M$-4.54M
EPS (diluted)$-3.53$-1.89$-0.73$-1.70$-0.31

Analyst forecast

Forecast

Consensus (16 analysts)

buy

Avg. price target

$30.29+173.62%

  • Strong buy 1
  • Buy 11
  • Hold 2
  • Sell 2
  • Strong sell 0

Target range

Low $6.00High $57.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.93 vs $-0.77
Surprise
-20.78%

MLTX news

All MLTX news

MoonLake Immunotherapeutics peers

Health Care sector
MLTX peer companies
CompanyPrice% ChgMarket capCompare
SVRASavara Inc.4.26-18.23%$939.86Mvs MLTX
CYRXCryoPort Inc.19.05-2.56%$964.87Mvs MLTX
SPTXSeaport Therapeutics Inc.18.05-1.47%$966.23Mvs MLTX
AKTSAktis Oncology Inc.16.15-1.52%$901.14Mvs MLTX
OMEROmeros Corporation13.21-5.71%$983.66Mvs MLTX
LTGOLatigo Biotherapeutics Inc.13.00-1.81%$861.89Mvs MLTX
ANROAlto Neuroscience Inc.25.37-4.30%$1.02Bvs MLTX
MTRIMentari Therapeutics Inc.14.70-3.57%$856.94Mvs MLTX

Indexes, lists and sector

MoonLake Immunotherapeutics stock FAQ

What is MoonLake Immunotherapeutics's stock price today?

MLTX last traded at $11.07 as of Nov 20, 4:00 PM EST, up 0.36% on the day. Prices are delayed at least 15 minutes.

Who is MoonLake Immunotherapeutics's CEO?

Dr. Jorge Santos da Silva Ph.D. is the chief executive officer of MoonLake Immunotherapeutics Class A, which has about 130 employees.

What is the MLTX 52-week high?

The 52-week high for MLTX is $23.29 and the 52-week low is $9.46. The stock is currently 52.5% below its high.

Compare MLTX